{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:12:01Z","timestamp":1795111921388,"version":"4.10.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000321","name":"World Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003173","name":"Crafoordska Stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Prostate Cancer Federation M\u00e4rta Winkler Foundation"},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Insulin resistance is a hypothesised biological mechanism linking obesity with prostate cancer (PCa) death. Data in support of this hypothesis is limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included 259,884 men from eight European cohorts, with 11,760 incident PCa\u2019s and 1784 PCa deaths during follow-up. We used the triglyceride-glucose (TyG) index as indicator of insulin resistance. We analysed PCa cases with follow-up from PCa diagnosis, and the full cohort with follow-up from the baseline cancer-free state, thus incorporating both PCa incidence and death. We calculated hazard ratios (HR) and the proportion of the total effect of body mass index (BMI) on PCa death mediated through TyG index.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the PCa-case-only analysis, baseline TyG index was positively associated with PCa death (HR per 1-standard deviation: 1.11, 95% confidence interval (CI); 1.01\u20131.22), and mediated a substantial proportion of the baseline BMI effect on PCa death (HR<jats:sub>total effect<\/jats:sub> per 5-kg\/m<jats:sup>2<\/jats:sup> BMI: 1.24; 1.14\u20131.35, of which 28%; 4%\u201352%, mediated). In contrast, in the full cohort, the TyG index was not associated with PCa death (HR: 1.03; 0.94-1.13), hence did not substantially mediate the effect of BMI on PCa death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Insulin resistance could be an important pathway through which obesity accelerates PCa progression to death.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-023-02526-1","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T12:03:11Z","timestamp":1702382591000},"page":"308-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts"],"prefix":"10.1038","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-3435","authenticated-orcid":false,"given":"Josef","family":"Fritz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia H. J.","family":"Jochems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9096-5257","authenticated-orcid":false,"given":"Tone","family":"Bj\u00f8rge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-304X","authenticated-orcid":false,"given":"Angela M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6808-4405","authenticated-orcid":false,"given":"Christel","family":"H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-1002","authenticated-orcid":false,"given":"Hanno","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-8535","authenticated-orcid":false,"given":"Gabriele","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Zitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-9207","authenticated-orcid":false,"given":"Anders","family":"Engeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-6891","authenticated-orcid":false,"given":"Sophia","family":"Harlid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-6310","authenticated-orcid":false,"given":"Isabel","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-0557","authenticated-orcid":false,"given":"Tanja","family":"Stocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"2526_CR1","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.eururo.2012.11.013","volume":"63","author":"EH Allott","year":"2013","unstructured":"Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63:800\u20139.","journal-title":"Eur Urol"},{"key":"2526_CR2","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/ijc.31553","volume":"143","author":"X Fang","year":"2018","unstructured":"Fang X, Wei J, He X, Lian J, Han D, An P, et al. Quantitative association between body mass index and the risk of cancer: a global Meta-analysis of prospective cohort studies. Int J Cancer. 2018;143:1595\u2013603.","journal-title":"Int J Cancer"},{"key":"2526_CR3","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1002\/ijc.33150","volume":"147","author":"SHJ Jochems","year":"2020","unstructured":"Jochems SHJ, Stattin P, H\u00e4ggstr\u00f6m C, J\u00e4rvholm B, Orho-Melander M, Wood AM, et al. Height, body mass index and prostate cancer risk and mortality by way of detection and cancer risk category. Int J Cancer. 2020;147:3328\u201338.","journal-title":"Int J Cancer"},{"key":"2526_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01606-8","volume":"10","author":"J Shi","year":"2021","unstructured":"Shi J, Zhao L, Gao Y, Niu M, Yan M, Chen Y, et al. Associating the risk of three urinary cancers with obesity and overweight: an overview with evidence mapping of systematic reviews. Syst Rev. 2021;10:58.","journal-title":"Syst Rev"},{"key":"2526_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2019.09.007","volume":"31","author":"JM Genkinger","year":"2020","unstructured":"Genkinger JM, Wu K, Wang M, Albanes D, Black A, van den Brandt PA, et al. Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in the pooling project of prospective studies of diet and cancer. Ann Oncol. 2020;31:103\u201314.","journal-title":"Ann Oncol"},{"key":"2526_CR6","doi-asserted-by":"publisher","first-page":"j477","DOI":"10.1136\/bmj.j477","volume":"356","author":"M Kyrgiou","year":"2017","unstructured":"Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477.","journal-title":"BMJ"},{"key":"2526_CR7","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s10552-015-0654-9","volume":"26","author":"NM Davies","year":"2015","unstructured":"Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, et al. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control. 2015;26:1603\u201316.","journal-title":"Cancer Causes Control"},{"key":"2526_CR8","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/pros.23001","volume":"75","author":"A Cantarutti","year":"2015","unstructured":"Cantarutti A, Bonn SE, Adami H-O, Gr\u00f6nberg H, Bellocco R, B\u00e4lter K. Body mass index and mortality in men with prostate cancer. Prostate. 2015;75:1129\u201336.","journal-title":"Prostate"},{"key":"2526_CR9","doi-asserted-by":"crossref","unstructured":"Zhong S, Yan X, Wu Y, Zhang X, Chen L, Tang J, et al. Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis. Vol. 19, Prostate cancer and prostatic diseases. Nature Publishing Group; 2016. p. 122\u201331.","DOI":"10.1038\/pcan.2015.64"},{"key":"2526_CR10","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1200\/JCO.19.02185","volume":"38","author":"AN Troeschel","year":"2020","unstructured":"Troeschel AN, Hartman TJ, Jacobs EJ, Stevens VL, Gansler T, Flanders WD, et al. Postdiagnosis body mass index, weight change, and mortality from prostate cancer, cardiovascular disease, and all causes among survivors of nonmetastatic prostate cancer. J Clin Oncol. 2020;38:2018.","journal-title":"J Clin Oncol"},{"key":"2526_CR11","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.3390\/cancers13164169","volume":"13","author":"M Rivera-Izquierdo","year":"2021","unstructured":"Rivera-Izquierdo M, P\u00e9rez de Rojas J, Mart\u00ednez-Ruiz V, P\u00e9rez-G\u00f3mez B, S\u00e1nchez M-J, Khan KS, et al. Obesity as a risk factor for prostate cancer mortality: a systematic review and dose-response meta-analysis of 280,199 patients. Cancers. 2021;13:4169.","journal-title":"Cancers"},{"key":"2526_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0829-8","volume":"31","author":"MB Hu","year":"2014","unstructured":"Hu MB, Xu H, Bai PD, Jiang HW, Ding Q. Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients. Med Oncol. 2014;31:89.","journal-title":"Med Oncol"},{"key":"2526_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.juro.2014.04.086","volume":"192","author":"HJ Chalfin","year":"2014","unstructured":"Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Alai H, Feng Z, et al. Obesity and long-term survival after radical prostatectomy. J Urol. 2014;192:1100\u20134.","journal-title":"J Urol"},{"key":"2526_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/pcan.2016.47","volume":"20","author":"AC Vidal","year":"2017","unstructured":"Vidal AC, Howard LE, Sun SX, Cooperberg MR, Kane CJ, Aronson WJ, et al. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer Prostatic Dis. 2017;20:72\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2526_CR15","first-page":"345","volume":"10","author":"C Rodriguez","year":"2001","unstructured":"Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomark Prev. 2001;10:345\u201353.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2526_CR16","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl J Med. 2003;348:1625\u201338.","journal-title":"N. Engl J Med"},{"key":"2526_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1158\/1940-6207.CAPR-10-0229","volume":"4","author":"Y Cao","year":"2011","unstructured":"Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res Cancer Prev Res (Philos). 2011;4:486\u2013501.","journal-title":"Cancer Prev Res Cancer Prev Res (Philos)"},{"key":"2526_CR18","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MOU.0000000000000429","volume":"27","author":"M Abufaraj","year":"2017","unstructured":"Abufaraj M, Mari A, Mansy K, Sievert K. Obesity and its implications on oncological urological surgery. Curr Opin Urol. 2017;27:446\u201355. Sep 1","journal-title":"Curr Opin Urol"},{"key":"2526_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.urology.2019.05.053","volume":"133","author":"S Knipper","year":"2019","unstructured":"Knipper S, Mazzone E, Mistretta F, Palumbo C, Tian Z, Briganti A, et al. Impact of obesity on perioperative outcomes at robotic-assisted and open radical prostatectomy: results from the national inpatient sample. Urology. 2019;133:135\u201344.","journal-title":"Urology"},{"key":"2526_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrurol.2014.207","volume":"11","author":"S Freedland","year":"2014","unstructured":"Freedland S, Mucci L. Prostate cancer: Is active surveillance safe for obese patients? Nat Rev Urol. 2014;11:489\u201390.","journal-title":"Nat Rev Urol"},{"key":"2526_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc1408","volume":"4","author":"EE Calle","year":"2004","unstructured":"Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579\u201391.","journal-title":"Nat Rev Cancer"},{"key":"2526_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrc3967","volume":"15","author":"AG Renehan","year":"2015","unstructured":"Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15:484\u201398.","journal-title":"Nat Rev Cancer"},{"key":"2526_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.eururo.2014.06.005","volume":"66","author":"B Bhindi","year":"2014","unstructured":"Bhindi B, Kulkarni G, Finelli A, Alibhai S, Hamilton R, Toi A, et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol. 2014;66:841\u20138.","journal-title":"Eur Urol"},{"key":"2526_CR24","doi-asserted-by":"publisher","first-page":"e11771","DOI":"10.1097\/MD.0000000000011771","volume":"97","author":"ZL Guo","year":"2018","unstructured":"Guo ZL, Weng XT, Chan FL, Gong LL, Xiang ST, Gan S, et al. Serum C-peptide concentration and prostate cancer: a meta-analysis of observational studies. Medicine. 2018;97:e11771.","journal-title":"Medicine"},{"key":"2526_CR25","doi-asserted-by":"crossref","unstructured":"Saboori S, Rad EY, Birjandi M, Mohiti S, Falahi E .Serum insulin level, HOMA-IR and prostate cancer risk: a systematic review and meta-analysis. Vol. 13, Diabetes and metabolic syndrome: clinical research and reviews. Elsevier Ltd; 2019. p. 110\u20135.","DOI":"10.1016\/j.dsx.2018.08.031"},{"key":"2526_CR26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S1470-2045(08)70235-3","volume":"9","author":"J Ma","year":"2008","unstructured":"Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen P, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9:1039\u201347.","journal-title":"Lancet Oncol"},{"key":"2526_CR27","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1016\/j.ejca.2005.09.003","volume":"41","author":"J Hammarsten","year":"2005","unstructured":"Hammarsten J, H\u00f6gstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41:2887\u201395.","journal-title":"Eur J Cancer"},{"key":"2526_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mend\u00eda","year":"2008","unstructured":"Simental-Mend\u00eda LE, Rodr\u00edguez-Mor\u00e1n M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299\u2013304.","journal-title":"Metab Syndr Relat Disord"},{"key":"2526_CR29","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1210\/jc.2010-0288","volume":"95","author":"F Guerrero-Romero","year":"2010","unstructured":"Guerrero-Romero F, Simental-Mend\u00eda LE, Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E, Ramos-Zavala MG, Hern\u00e1ndez-Gonz\u00e1lez SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3347\u201351.","journal-title":"J Clin Endocrinol Metab"},{"key":"2526_CR30","doi-asserted-by":"publisher","first-page":"e0149731","DOI":"10.1371\/journal.pone.0149731","volume":"11","author":"L-K Er","year":"2016","unstructured":"Er L-K, Wu S, Chou H-H, Hsu L-A, Teng M-S, Sun Y-C, et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals. PLoS One. 2016;11:e0149731.","journal-title":"PLoS One"},{"key":"2526_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ije\/dyz053","volume":"49","author":"J Fritz","year":"2020","unstructured":"Fritz J, Bj\u00f8rge T, Nagel G, Manjer J, Engeland A, H\u00e4ggstr\u00f6m C, et al. The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. Int J Epidemiol. 2020;49:193\u2013204.","journal-title":"Int J Epidemiol"},{"key":"2526_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/EDE.0b013e31821db37e","volume":"22","author":"TJ VanderWeele","year":"2011","unstructured":"VanderWeele TJ. Causal mediation analysis with survival data. Epidemiology. 2011;22:582\u20135.","journal-title":"Epidemiology"},{"key":"2526_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"2526_CR34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2105\/AJPH.2018.304337","volume":"108","author":"MA Hern\u00e1n","year":"2018","unstructured":"Hern\u00e1n MA. The C-word: scientific euphemisms do not improve causal inference from observational data. Am J Public Health. 2018;108:616\u20139.","journal-title":"Am J Public Health"},{"key":"2526_CR35","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/ije\/dyl233","volume":"35","author":"Studies Collaboration Fibrinogen.","year":"2006","unstructured":"Studies Collaboration Fibrinogen. Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27 247 adults in 15 prospective studies. Int J Epidemiol. 2006;35:1570\u20138.","journal-title":"Int J Epidemiol"},{"key":"2526_CR36","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/sim.3530","volume":"28","author":"AM Wood","year":"2009","unstructured":"Wood AM, Thompson SG, Kostis JB, Wilson AC, Wu K, Benderly M, et al. Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Stat Med. 2009;28:1067\u201392.","journal-title":"Stat Med"},{"key":"2526_CR37","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/ijc.30931","volume":"141","author":"EM Cespedes Feliciano","year":"2017","unstructured":"Cespedes Feliciano EM, Prentice RL, Aragaki AK, Neuhouser ML, Banack HR, Kroenke CH, et al. Methodological considerations for disentangling a risk factor\u2019s influence on disease incidence versus postdiagnosis survival: the example of obesity and breast and colorectal cancer mortality in the Women\u2019s Health Initiative. Int J Cancer. 2017;141:2281\u201390.","journal-title":"Int J Cancer"},{"key":"2526_CR38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","volume":"15","author":"MA Hern\u00e1n","year":"2004","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615\u201325.","journal-title":"Epidemiology"},{"key":"2526_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/EDE.0b013e31828c776c","volume":"24","author":"HR Banack","year":"2013","unstructured":"Banack HR, Kaufman JS. The \u201cObesity Paradox\u201d Explained. Epidemiology. 2013;24:461\u20132.","journal-title":"Epidemiology"},{"key":"2526_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/1055-9965.EPI-10-1006","volume":"20","author":"LP Wallner","year":"2011","unstructured":"Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, et al. The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomark Prev. 2011;20:501\u20138.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2526_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/pros.20852","volume":"69","author":"M Cox","year":"2009","unstructured":"Cox M, Gleave M, Zakikhani M, Bell R, Piura E, Vickers E, et al. Insulin receptor expression by human prostate cancers. Prostate. 2009;69:33\u201340.","journal-title":"Prostate"},{"key":"2526_CR42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fendo.2016.00132","volume":"7","author":"C Perks","year":"2016","unstructured":"Perks C, Zielinska H, Wang J, Jarrett C, Frankow A, Ladomery M, et al. Insulin receptor isoform variations in prostate cancer cells. Front Endocrinol. 2016;7:132.","journal-title":"Front Endocrinol"},{"key":"2526_CR43","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1093\/jnci\/djm231","volume":"99","author":"V Venkateswaran","year":"2007","unstructured":"Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 2007;99:1793\u2013800.","journal-title":"J Natl Cancer Inst"},{"key":"2526_CR44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fendo.2019.00481","volume":"10","author":"PL Sarkar","year":"2019","unstructured":"Sarkar PL, Lee W, Williams ED, Lubik AA, Stylianou N, Shokoohmand A, et al. Insulin enhances migration and invasion in prostate cancer cells by up-regulation of FOXC2. Front Endocrinol. 2019;10:481.","journal-title":"Front Endocrinol"},{"key":"2526_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00345-012-0902-5","volume":"31","author":"T Schnoeller","year":"2013","unstructured":"Schnoeller T, Jentzmik F, Rinnab L, Cronauer M, Damjanoski I, Zengerling F, et al. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol. 2013;31:253\u20139.","journal-title":"World J Urol"},{"key":"2526_CR46","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/1756287215597633","volume":"7","author":"JE Michaud","year":"2015","unstructured":"Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015;7:378\u201387.","journal-title":"Ther Adv Urol"},{"key":"2526_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1373\/clinchem.2009.133272","volume":"56","author":"H Li","year":"2010","unstructured":"Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56:34\u201343.","journal-title":"Clin Chem"},{"key":"2526_CR48","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1002\/ijc.24241","volume":"124","author":"J Stark","year":"2009","unstructured":"Stark J, Li H, Kraft P, Kurth T, Giovannucci E, Stampfer M, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J cancer. 2009;124:2683\u20139.","journal-title":"Int J cancer"},{"key":"2526_CR49","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1001\/jama.2016.4666","volume":"315","author":"S Afzal","year":"2016","unstructured":"Afzal S, Tybj\u00e6rg-Hansen A, Jensen GB, Nordestgaard BG. Change in body mass index associated with lowest mortality in Denmark, 1976-2013. JAMA. 2016;315:1989.","journal-title":"JAMA"},{"key":"2526_CR50","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1172\/JCI129186","volume":"129","author":"GI Smith","year":"2019","unstructured":"Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129:3978\u201389.","journal-title":"J Clin Invest"},{"key":"2526_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L, Westergren K, Holmberg L, T\u00e4lback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27\u201333.","journal-title":"Acta Oncol"},{"key":"2526_CR52","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","volume":"45","author":"IK Larsen","year":"2009","unstructured":"Larsen IK, Sm\u00e5stuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45:1218\u201331.","journal-title":"Eur J Cancer"},{"key":"2526_CR53","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/eurpub\/cks125","volume":"23","author":"M Hackl","year":"2013","unstructured":"Hackl M, Waldhoer T. Estimation of completeness of case ascertainment of Austrian cancer incidence data using the flow method. Eur J Public Health. 2013;23:889\u201393.","journal-title":"Eur J Public Health"},{"key":"2526_CR54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejca.2014.10.025","volume":"51","author":"K Tomic","year":"2015","unstructured":"Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51:101\u201311.","journal-title":"Eur J Cancer"},{"key":"2526_CR55","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/S0140-6736(14)60991-0","volume":"383","author":"D Wormser","year":"2014","unstructured":"Wormser D, Wood AM, Di Angelantonio E, Thompson SG, Danesh J. Metabolic mediators of body-mass index and cardiovascular risk. Lancet. 2014;383:2042\u20133.","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02526-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02526-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02526-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T20:02:44Z","timestamp":1705953764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02526-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,10]]}},"alternative-id":["2526"],"URL":"https:\/\/doi.org\/10.1038\/s41416-023-02526-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"7 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by research ethics committees in the respective countries (Norway: Regional Committee for Medical and Health Research Ethics, no 2012\/2271\/REC South-East, Sweden: EPN Ume\u00e5, no 2012-354-31M and no 2015-7-32M, and EPN Lund, no 2016\/564 and 2020-01571, Austria: Ethics Committee of the province of Vorarlberg, no 2006-6\/2). Individual informed consent for this analysis was waived since we only used de-identified data routinely collected during the health screening process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}